Skip to main content
Premium Trial:

Request an Annual Quote

MDNA Taps Phi Life Sciences to Distribute Prostate Cancer Liquid Biopsy Test in US

NEW YORK (GenomeWeb) – Molecular diagnostics firm MDNA Life Sciences said today that it signed an agreement making Phi Life Sciences the first US distributor of its proprietary liquid biopsy test for prostate cancer, the Prostate Mitomic Test (PMT).

MDNA has pioneered a method for liquid biopsy testing based on analysis of the mitochondrial genome. PMT is a liquid biopsy test intended to determine which men with clinical suspicion of prostate cancer are likely to have high-grade disease that may require immediate intervention. The test's negative predictive value can also help identify cases that can safely delay or forego immediate biopsy.

"Launching PMT with Phi will allow us to quickly build a user base to drive market acceptance and adoption," said MDNA CEO Chris Mitton in a statement. "This valuable partnership will also help with the collection of post-market data for PMT to demonstrate clinical utility."

In addition to the prostate cancer test, MDNA is also working on a test for endometriosis. It formed a collaboration earlier this month with the University of Oxford to further develop and validate this assay.


The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.